BeautyHealth Adopts $200M Stock Buyback Plan
September 27, 12:16 PM
Beauty Health Co (NASDAQ:SKIN) Board of Directors has authorized a share repurchase program of up to $200 million of outstanding common…
40,106 ETH Was Just Transferred Between 2 Wallets
September 27, 12:13 PM
What happened: $52,105,196 worth of Ethereum (CRYPTO: ETH) was just moved between 2 anonymous cryptocurrency wallets in a single transaction.
This mysterious person's Ethereum wallet address has been identified as: 0x87c0bb7dc7bae005f3ee73671bf04f3ed0d49efb
Why Are Bellerophon Shares Jumping Today?
September 27, 12:07 PM
The FDA has accepted Bellerophon Therapeutics Inc’s (NASDAQ:BLPH) proposal to reduce the study size for its ongoing registrational REBUILD Phase 3…
NLS Pharmaceutics’ Shares Fall As Data From Narcolepsy Candidate Fails To Cheer Investors
September 27, 12:02 PM
NLS Pharmaceutics Ltd (NASDAQ:NLSP) announced topline results from its Phase 2a trial evaluating its lead product candidate, Quilience (Mazindol ER), in…
Seagen, Zai Lab Ink Regional Strategic Licensing Agreement For Cervical Cancer Treatment
September 27, 11:57 AM
Seagen Inc (NASDAQ:SGEN) and Zai Lab Limited (NASDAQ:ZLAB) have announced an exclusive collaboration and license agreement for the development and commercialization of TIVDAK…
Why Ingredion Shares Are Soaring Higher Today
September 27, 11:37 AM
Ingredion Inc (NYSE: INGR) shares are trading higher by 6.12% to $83.82 Tuesday morning after the company raised its quarterly dividend by 9% and authorized a 6 million share buyback.
What Else?
What’s Going On With Tesla Stock Today
September 27, 11:36 AM
Tesla Inc (NASDAQ: TSLA) shares are trading higher by 4.12% to $287.39 Tuesday morning following a report suggesting the company expects a high volume of deliveries at the end of the quarter.
What Happened?
X4 Pharma Highlights New Data Supporting Mavorixafor’s Broad Potential In Chronic Neutropenia
September 27, 10:49 AM
X4 Pharmaceuticals Inc (NASDAQ:XFOR) announced new data from its Phase 1b trial evaluating the ability of its lead clinical candidate, mavorixafor,…